SYN

Synthetic Biologics, Inc. [SYN] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

SYN Stock Summary

In the News

12:19 28 Mar 2024 SYN

Synthetic Biologics, Inc. (SYN) CEO Steven Shallcross on Q2 2022 Results - Earnings Call Transcript

Synthetic Biologics, Inc. (NYSE:SYN ) Q2 2022 Earnings Conference Call August 11, 2022 8:30 AM ET Company Participants Chris Calabrese - Investor Relations Steven Shallcross - Chief Executive & Chief Financial Officer Manel Cascallo - General Director of VCN & European Operations Conference Call Participants Laura Suriel - Alliance Global Partners Michael Okunewitch - Maxim Group Operator Good day, and welcome to the Synthetic Biologics' Second Quarter 2022 Earnings Call. Today's conference is being recorded.

05:06 28 Mar 2024 SYN

Synthetic Biologics, Inc. (SYN) CEO Steven Shallcross on Q1 2022 Results - Earnings Call Transcript

Synthetic Biologics, Inc. (NYSE:SYN ) Q1 2022 Earnings Conference Call May 16, 2022 9:00 AM ET Company Participants Dean Schwartz - LifeSci Advisors, IR Steven Shallcross - CEO and CFO Manel Cascallo - General Director of VCN & European Operations Conference Call Participants Jim Molloy - Alliance Global Partners Leland Gershell - Oppenheimer Operator Greetings, and welcome to Synthetic Biologics' First Quarter 2022 Earnings Conference Call. At this time all participants are in a listen-only mode.

08:00 28 Mar 2024 SYN

Synthetic Biologics to Host Conference Call and Webcast to Discuss First Quarter 2022 Operational Highlights and Financial Results

ROCKVILLE, Md., May 09, 2022 (GLOBE NEWSWIRE) -- Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company developing therapeutics designed to treat diseases in areas of high unmet need, today announced that it plans to host a conference call on Monday, May 16, 2022, at 8:30 a.m. ET to discuss its financial results for the quarter ended March 31, 2022 and provide a corporate update.

01:45 28 Mar 2024 SYN

5 Top Biotech Penny Stocks Under $1 To Watch This Week

Top penny stocks to watch under $1 in April if you like Biotech stocks. The post 5 Top Biotech Penny Stocks Under $1 To Watch This Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

11:09 28 Mar 2024 SYN

Synthetic Biologics, Inc. (SYN) CEO Steven Shallcross on Q4 2021 Results - Earnings Call Transcript

Synthetic Biologics, Inc. (SYN) CEO Steven Shallcross on Q4 2021 Results - Earnings Call Transcript

04:30 28 Mar 2024 SYN

Synthetic Biologics to Host Conference Call and Webcast to Discuss 2021 Year End Operational Highlights and Financial Results

ROCKVILLE, Md., March 10, 2022 (GLOBE NEWSWIRE) -- Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company developing therapeutics designed to treat diseases in areas of high unmet need, today announced that it plans to host a conference call on Wednesday, March 16, 2022, at 4:30 p.m. ET to discuss its financial results for the year ended December 31, 2021 and provide a corporate update.

07:15 28 Mar 2024 SYN

Synthetic Biologics to Present at 2022 BIO CEO & Investor Conference

ROCKVILLE, Md., Feb. 9, 2022 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company developing therapeutics designed to treat diseases in areas of high unmet need, today announced that the Company will be presenting at the 2022 BIO CEO & Investor Conference being held February 14-17, 2022.

06:53 28 Mar 2024 SYN

Synthetic Biologics, Inc.'s (SYN) CEO Steven Shallcross on Q3 2021 Results - Earnings Call Transcript

Synthetic Biologics, Inc.'s (SYN) CEO Steven Shallcross on Q3 2021 Results - Earnings Call Transcript

12:39 28 Mar 2024 SYN

5 Top Penny Stocks To Buy For Under $5 On Webull Today

Are these penny stocks on your Webull watch list? The post 5 Top Penny Stocks To Buy For Under $5 On Webull Today appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

07:00 28 Mar 2024 SYN

Synthetic Biologics to Report 2021 Third Quarter Operational Highlights and Financial Results on November 3, 2021

ROCKVILLE, Md., Oct. 26, 2021 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent and treat gastrointestinal (GI) diseases in areas of high unmet need, announced today that the Company intends to release its operational highlights and financial results for the quarter ended September 30, 2021 on Wednesday, November 3, 2021, and to host a conference call the same day at 4:30 p.m.

SYN Financial details

Company Rating
Buy
Market Cap
16.16M
Income
-18.02M
Revenue
0
Book val./share
2.41
Cash/share
1.83
Dividend
-
Dividend %
-
Employees
16
Optionable
No
Shortable
Yes
Earnings
14 Mar 2023
P/E
-0.8
Forward P/E
-
PEG
-3.6028797018964E+14
P/S
-
P/B
0.33
P/C
0.56
P/FCF
-0.81
Quick Ratio
4.19
Current Ratio
4.68
Debt / Equity
0.05
LT Debt / Equity
0.04
-
-
EPS (TTM)
-1.17
EPS next Y
-
EPS next Q
-
EPS this Y
9.4%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
-44.12%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
664.07%
Inst Trans
99.13%
ROA
-29%
ROE
-37%
ROC
-0.37%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
15.84M
Shs Float
15.54M
-
-
-
-
Target Price
-
52W Range
0.7-4.55
52W High
-
52W Low
-
RSI
16
Rel Volume
0.36
Avg Volume
160.39K
Volume
57.79K
Perf Week
49.91%
Perf Month
-
Perf Quarter
-
Perf Half Y
0%
-
-
-
-
Beta
1.38873
-
-
Volatility
0.11%, 0.13%
Prev Close
52.22%
Price
1.02
Change
42.62%

SYN Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2022-12-31

Metric History 2018-12-312019-12-312020-12-312021-12-31 2022-12-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
00000
Net income per share
-21.45-9.31-5.28-1.17-1.28
Operating cash flow per share
-27.72-8.44-6.4-1.06-1.24
Free cash flow per share
-27.74-8.44-6.41-1.06-1.25
Cash per share
46.49.153.285.522.73
Book value per share
47.118.744.225.373.38
Tangible book value per share
42.456.992.775.373.2
Share holders equity per share
47.118.744.225.373.38
Interest debt per share
00.440.250.130.08
Market cap
349.02K833.25K728.14K3.32M15.63M
Enterprise value
-28.57M-13.49M-5.03M-62.48M-24.47M
P/E ratio
-0.03-0.05-0.07-0.23-0.79
Price to sales ratio
00000
POCF ratio
-0.02-0.06-0.06-0.26-0.82
PFCF ratio
-0.02-0.06-0.06-0.26-0.81
P/B Ratio
0.010.060.090.050.3
PTB ratio
0.010.060.090.050.3
EV to sales
00000
Enterprise value over EBITDA
2.180.90.514.411.13
EV to operating cash flow
1.650.970.414.851.28
EV to free cash flow
1.650.970.414.841.27
Earnings yield
-38.3-18.37-13.79-4.3-1.26
Free cash flow yield
-49.53-16.65-16.72-3.89-1.23
Debt to equity
00.050.060.020.03
Debt to assets
00.040.060.020.02
Net debt to EBITDA
2.210.950.584.641.86
Current ratio
8.723.112.6719.376.45
Interest coverage
000-2.38K45.82
Income quality
1.290.911.210.90.97
Dividend Yield
33.470.631.90.450
Payout ratio
-0.87-0.03-0.14-0.10
Sales general and administrative to revenue
00000
Research and developement to revenue
00000
Intangibles to total assets
00000.08
Capex to operating cash flow
00000.01
Capex to revenue
00000
Capex to depreciation
-0.030-0.04-0.16-1.36
Stock based compensation to revenue
00000
Graham number
150.7842.7822.4111.899.89
ROIC
-0.78-1.01-1.14-0.21-0.37
Return on tangible assets
-0.44-0.89-1.19-0.2-0.3
Graham Net
40.485.661.85.121.6
Working capital
26.13M11.15M4.97M65.3M38.46M
Tangible asset value
26.46M11.49M5.26M65.41M49.04M
Net current asset value
25.83M10.68M4.78M63.9M28.22M
Invested capital
00.050.060.020.03
Average receivables
23K1.5K236K234.5K0
Average payables
1.53M1.67M1.6M705K719.5K
Average inventory
00000
Days sales outstanding
00000
Days payables outstanding
00000
Days of inventory on hand
00000
Receivables turnover
00000
Payables turnover
00000
Inventory turnover
00000
ROE
-0.46-1.07-1.25-0.22-0.38
Capex per share
-0.01000-0.01

Quarterly Fundamentals Overview

Last date of statement is 2023-09-30 for Q3

Metric History 2022-09-302022-12-312023-03-312023-06-30 2023-09-30
2.02K2.02K2.02K2.02K2.02K
Revenue per share
00000
Net income per share
-0.34-0.34-0.3-0.34-0.19
Operating cash flow per share
0-0.33-0.3700
Free cash flow per share
0-0.33-0.3700
Cash per share
3.242.732.392.261.83
Book value per share
3.563.383.162.972.41
Tangible book value per share
3.463.22.972.782.25
Share holders equity per share
3.563.383.162.972.41
Interest debt per share
0.120.110.140.160.12
Market cap
15.37M15.63M15.43M15.47M17.38M
Enterprise value
-33.47M-24.47M-18.18M-16.42M-11.7M
P/E ratio
-0.72-0.76-0.86-0.76-1.32
Price to sales ratio
00000
POCF ratio
0-3.12-2.7500
PFCF ratio
0-3.06-2.7500
P/B Ratio
0.280.30.320.340.42
PTB ratio
0.280.30.320.340.42
EV to sales
00000
Enterprise value over EBITDA
6.673.663.512.822.77
EV to operating cash flow
04.883.2400
EV to free cash flow
04.783.2400
Earnings yield
-0.35-0.33-0.29-0.33-0.19
Free cash flow yield
0-0.33-0.3600
Debt to equity
0.030.030.050.050.05
Debt to assets
0.020.020.040.040.03
Net debt to EBITDA
9.7466.495.486.9
Current ratio
46.454.684.163.98
Interest coverage
-28.01221.213.9900
Income quality
00.971.2500
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
00000
Research and developement to revenue
00000
Intangibles to total assets
0.050.080.080.090.09
Capex to operating cash flow
00.02000
Capex to revenue
00000
Capex to depreciation
0-2.83-0.2500
Stock based compensation to revenue
00000
Graham number
5.255.064.594.733.24
ROIC
-0.09-0.09-0.09-0.12-0.08
Return on tangible assets
-0.07-0.08-0.07-0.08-0.06
Graham Net
1.921.61.241.090.79
Working capital
39.54M38.46M31.68M28.83M26.02M
Tangible asset value
53.9M49.04M44.97M42.13M38.42M
Net current asset value
32.19M28.22M23M20.27M17.11M
Invested capital
0.030.030.050.050.05
Average receivables
139K0000
Average payables
886.5K842.5K697.5K610.5K787K
Average inventory
00000
Days sales outstanding
00000
Days payables outstanding
00000
Days of inventory on hand
00000
Receivables turnover
00000
Payables turnover
00000
Inventory turnover
00000
ROE
-0.1-0.1-0.09-0.11-0.08
Capex per share
0-0.01000

SYN Frequently Asked Questions

What is Synthetic Biologics, Inc. stock symbol ?

Synthetic Biologics, Inc. is a US stock , located in Rockville of Maryland and trading under the symbol SYN

What is Synthetic Biologics, Inc. stock quote today ?

Synthetic Biologics, Inc. stock price is $1.02 today.

Is Synthetic Biologics, Inc. stock public?

Yes, Synthetic Biologics, Inc. is a publicly traded company.

Something similar

Top by Market Cap
Same Sector
Check Those
Similar Market Cap